Missing Script · Evidence review
Sometimes supportive care is technologically simple. Holding ice chips in the mouth during chemotherapy sounds almost too ordinary to count as an intervention.
For two treatment settings, however, oral cryotherapy has real evidence. The cold temporarily narrows blood vessels in the mouth, reducing exposure of the lining to a drug while its blood level is high. That logic only works when the treatment and timing fit.
The strongest evidence: bolus 5-FU
A Cochrane review combined five studies involving 444 adults receiving fluorouracil-based chemotherapy for solid tumors. Oral cryotherapy reduced the risk of developing mucositis of any severity, with a risk ratio of 0.61—about a 39% relative reduction. The reviewers rated this moderate-quality evidence.
The MASCC/ISOO guideline therefore recommends 30 minutes of oral cryotherapy for people receiving bolus 5-FU. “Bolus” is not a minor detail. Continuous-infusion 5-FU remains in circulation much longer, so brief cooling does not reproduce the same exposure reduction.
High-dose melphalan before transplant
A prospective randomized study in people with multiple myeloma receiving high-dose melphalan before autologous stem-cell transplantation found grade 3–4 mucositis in 14% with cryotherapy versus 74% with room-temperature saline mouth rinses. Severe mouth injury can affect pain, opioid use, nutrition and the need for intravenous support, so that difference is clinically meaningful.
Across five melphalan studies involving 270 adults, the Cochrane review estimated a lower risk of mucositis of any severity, but the confidence interval included no difference. Evidence for reducing severe mucositis was more convincing. MASCC/ISOO now recommends cryotherapy when autologous transplant conditioning includes high-dose melphalan.
Where the evidence stops
The same guideline found insufficient evidence to recommend cryotherapy for continuous 5-FU, head-and-neck radiation, treatment of established mucositis or other short-infusion drugs as a broad category. A 2020 systematic guideline review reached the same regimen-specific conclusions.
This is an important evidence-literacy lesson: a low-cost intervention can work and still have narrow boundaries. “Ice helps mouth sores” is too broad. “A timed cooling protocol helps prevent mucositis with these particular drugs” is much closer to the evidence.
Practical safety
Cooling can be uncomfortable and may cause headache, dental sensitivity or nausea. Chewing hard ice can damage teeth. A clinical protocol may use ice chips, cold water or another controlled method, and the infusion team should decide the timing. People with swallowing problems, aspiration risk, significant dental disease or cold sensitivity may need a different approach.
Basic oral care still matters. Cryotherapy does not replace routine mouth assessment, gentle hygiene or prompt evaluation of fever, inability to drink, bleeding, severe pain or suspected infection.
Questions for the care team
- Is my regimen bolus 5-FU, high-dose melphalan or something else?
- Does this infusion center use a standard oral-cooling protocol?
- Is cooling safe with my dental health and swallowing function?
- Whom should I call if mouth pain affects drinking or eating?
The intervention is simple. Using it accurately requires knowing exactly which treatment is being given.
Evidence checked October 5, 2026. Educational review; discuss individual treatment, exercise and supplement decisions with your care team.
